Please login to the form below

Not currently logged in
Email:
Password:

Xofigo

This page shows the latest Xofigo news and features for those working in and with pharma, biotech and healthcare.

Pharma sales help Bayer escape the worst from a bumpy 2017

Pharma sales help Bayer escape the worst from a bumpy 2017

The two brands, along with cancer drugs Xofigo and Stivarga and pulmonary hypertension treatment Adempas, are seen by the company as its key growth brands.

Latest news

  • EMA clears Bayer's Stivarga for liver cancer EMA clears Bayer's Stivarga for liver cancer

    Stivarga is a key component among a new generation of pharma products - along with cancer drug Xofigo (radium-223 dichloride), anticoagulant Xarelto (rivaroxaban), ophthalmic therapy Eylea (aflibercept) and pulmonary arterial hypertension

  • Xarelto and Eylea continue to dominate Bayer's pharma sales Xarelto and Eylea continue to dominate Bayer's pharma sales

    The two products accounted for around 28% of Bayer's total pharma sales last year and are regarded as key growth products for the firm, along with its cancer drugs Xofigo ... Last year Xofigo (radium-223 dichloride) brought in 331m (up 29%) and Adempas

  • Xarelto leads the charge at Bayer Xarelto leads the charge at Bayer

    There were also gains for Eylea (aflibercept) for age-related macular degeneration (AMD) as well as prostate cancer drug Xofigo (radium Ra 223 dichloride) and Adempas (riociguat) for pulmonary artery hypertension.

  • Japanese approvals for GSK, AZ and Bayer Japanese approvals for GSK, AZ and Bayer

    Finally, Bayer has won Japanese approval for Xofigo (radium-223 dichloride, radium-223), its radiopharmaceutical drug for the treatment of patients with castration-resistant prostate cancer and bone metastases. ... Bayer has said it expects 50%-plus

  • Price cut keeps Kadcyla on CDF Price cut keeps Kadcyla on CDF

    Bayer's Xofigo (radium-223 dichloride) for castration-resistant prostate cancer with bone metastases remains under appeal.

More from news
Approximately 10 fully matching, plus 14 partially matching documents found.

Latest Intelligence

  • Pharma deals during June 2014 Pharma deals during June 2014

    Bayer paid 50m ($68m) upfront payment with further milestones in return for global rights which should complement Xofigo (from the acquisition of Algeta). The companies will jointly fund the phase III

  • Deal Watch table for November 2013 Deal Watch table for November 2013

    Hyperlipidemia. 2, 600. Algeta / Bayer. Acquisition. Buys out deal for Xofigo radiotherapeutic for.

  • Pharma deals during November 2013 Pharma deals during November 2013

    Algeta, has been noted as being rather ungenerous, with room for upping the offer. This takeover was an obvious tactic bringing in the key the asset, Xofigo which has been under ... for 2012. Peak sales for Xofigo are expected to reach $1.5bn plus

More from intelligence
Approximately 0 fully matching, plus 3 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
GK Strategy

GK is award-winning independent communications agency specialising in delivering impactful strategies for clients across the healthcare market....

Latest intelligence

Alzheimer’s disease – is Europe prepared if a breakthrough treatment becomes available?
Healthcare leaders in the European Union should begin preparing for a breakthrough now...
The UK’s new five-year pricing agreement
Pharma has agreed to capped growth again - in exchange for uptake promises...
Digital applications are transforming the market access landscape
Organisations are leveraging new technology to implement a wider range of business models and, in essence, drive market access success by working smarter, faster and with greater economy....

Infographics